Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Brain Neoplasms 2Meningeal Carcinomatosis 1Glioblastoma 1

Interventions

Pemetrexed 5Topotecan 3Dexamethasone 3Bevacizumab 3osimertinib 2Vitamin B 12 2Trastuzumab 2Spinal Puncture 2Radiotherapy 2Methotrexate 2Folic Acid 2Cytarabine 2Busulfan 2trioctyl phosphine oxide 1trastuzumab deruxtecan 1tipifarnib 1merphos 1mafosfamide 1immunotoxin LMB-7 1epothilone B 1avelumab 1aflutinib 1XL647 1Transplantation, Autologous 1Temozolomide 1Rituximab 1Referral and Consultation 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Mental Status and Dementia Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Meningeal Carcinomatosis × XL647 × Clear all
NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation, LLC

Phase 2 Completed
36 enrolled 22 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡